ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes
Recurrence
Lymphoma
Myeloid Leukemia

Leukemia trials near Berlin, BE, DEU:

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (TUSCANY)

in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...

Enrolling
Leukemia, Myeloid, Acute
Chronic Myelomonocytic Leukemia
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

Phase 1, Phase 2

Aptose Biosciences

Berlin, Berlin, Germany and 33 other locations

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia. The study is funded by European Commission (HORIZON-MISS-2022-CAN...

Enrolling
Acute Myeloid Leukemia
Relapse/Recurrence
Drug: High intensity therapies
Drug: Low intensity therapies

Phase 3

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Berlin, Germany and 50 other locations

A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

Researchers are looking for a new way to treat a blood cancer called chronic myeloid leukemia (CML). Researchers want to learn if MK-4208 (T...

Enrolling
Chronic Myeloid Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drug: MK-4208

Phase 1, Phase 2

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Berlin, Germany and 53 other locations

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: AG-120

Phase 1, Phase 2

Celgene
Celgene

Berlin, Germany and 48 other locations

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (453 Ph1 CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how wel...

Active, not recruiting
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Drug: ABBV-453
Drug: Obinutuzumab

Phase 1

AbbVie
AbbVie

Berlin, Germany and 21 other locations

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retr...

Enrolling
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Obinutuzumab

Phase 2

AbbVie
AbbVie

Berlin, Germany and 57 other locations

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

generation (2G) Tyrosine Kinase Inhibitor (TKI) nilotinib (300 mg BID), in adult patients with newly diagnosed Positive Chronic Myelogenous Leukemia...

Active, not recruiting
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Drug: Nilotinib
Drug: Asciminib

Phase 3

Novartis
Novartis

Berlin, Germany and 118 other locations

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia...

Enrolling
LGLL - Large Granular Lymphocytic Leukemia
Aggressive NK Cell Leukemia
Drug: DR-01

Phase 1, Phase 2

Dren Bio

Berlin, Germany and 36 other locations

Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy (VENAZA-5S)

Acute myeloid leukemia (AML): continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cycle = standard of care for ...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: VEN+AZA-5

Phase 2

University of Leipzig

Berlin, Germany and 9 other locations

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Cytarabine
Drug: Bleximenib

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Berlin, Germany and 33 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems